Cardiac monitoring plays a key role in safeguarding heart health, especially in cardiology research and pharmaceutical trials. Now, new research is demonstrating how cardiac monitoring is instrumental to research well beyond its original contexts, transforming how sponsors use this tool in trials. A prime example is a recent study conducted by Ochsner Health, which directly illustrated the potential of using cardiac monitoring to examine the relationship between seizures and cardiac function in epilepsy patients. By using wearable ECG monitors, researchers have found that continuous, real-time cardiac monitoring can be applied well beyond the walls of cardiology practices.
As cardiac monitoring is increasingly effective in providing broad physiological insights for the entire body, we’re increasingly seeing it used to inform neurology, psychiatry, oncology, and more.
In this blog, we will cover:
For patients with epilepsy, seizures can be a life-threatening neurological event. Those diagnosed with epilepsy are at elevated risk for seizure-related cardiopulmonary complications, and even sudden unexpected death in epilepsy (SUDEP), which is linked to severe cardiac and respiratory compromise. The study conducted by Ochsner Health sought to help improve risk assessment and treatment for epilepsy patients in a neurological trial supported by Vivalink’s wearable ECG monitors. By using continuous heart monitoring during and after seizures, researchers explored the physiological connection between seizures and cardiac function.
Early findings showed that seizures disrupted the coordination between the heart’s upper and lower chambers, which could reduce oxygen flow to the brain and other organs. Apart from interfering with cardiac function, this adds to the risk of sudden cardiac death for patients, as they already exhibit irregular heart rhythms during seizures. Cardiac monitoring makes it possible to identify these patterns and identify high-risk patients, allowing for targeted interventions when needed.
The Ochsner study demonstrated the potential of cardiac monitoring in enhancing data quality as well. In the past, capturing seizure data has been a challenge. Traditional hospital monitors are at risk of detaching during a seizure, which breaks the data stream researchers need most. Wearable ECG monitors offer a solution to that problem through continuous, uninterrupted cardiac tracking that doesn’t restrict patient movement. In turn, this enables researchers to observe exactly what happens to the heart before, during, and after a seizure event. If consistent cardiac patterns emerge in advance of seizures, wearable sensors could one day provide early warning alerts, giving patients and caregivers the necessary time to intervene. Continuous monitoring opens the door to proactive, data-driven care that can make a critical difference in areas beyond just cardiac health.
As the Ochsner Health study expands the boundaries of cardiac monitoring, it reflects a broader advancement in how cardiac monitoring is used across therapeutic areas. Cardiac monitoring is a regulatory requirement in psychiatric drug development, as many drugs used to treat conditions like schizophrenia, bipolar disorder, and depression carry a risk of QT interval prolongation, a potentially dangerous change in the heart's electrical cycle. Consequently, ECG monitoring is built into the standard protocol for psychiatric clinical trials.
The value of cardiac monitoring goes well beyond regulatory compliance, though. Heart rate variability (HRV), for example, has emerged as a significant biomarker for emotional regulation, with low HRV correlating with high systemic stress and neurological dysfunction. This has made it a meaningful data point in studies of depression, anxiety, and PTSD. As technology continues to advance, cardiac markers are increasingly being explored as emotional biomarkers for mental health diagnostics.
Researchers are further exploring the cardiovascular system as a view into patient health through oncology, where cardiac biomarkers are being combined with behavioral data to develop dosing strategies and detect treatment responses earlier. We see this further explored in sleep studies when it comes to HRV, as an elevated heart rate during sleep has been associated with increased risk of Type 2 diabetes. Some studies have even correlated heart rate with cognitive load in high-stress driving situations.
What unites these applications is the need for continuous, high-fidelity data, something which periodic, clinic-based monitoring is unable to provide. A brief ECG snapshot cannot capture quick, intermittent events, a critical drawback when those events often carry the greatest clinical significance. Wearable ECGs, on the other hand, monitor patients around the clock in real-world conditions, all without disrupting their daily lives.
The Ochsner Health study illustrates the growing potential of what continuous cardiac monitoring can do, even in therapeutic areas outside cardiology and mandatory clinical trials use. Whether we’re looking at detecting seizure-related arrhythmias in neurology, tracking HRV as a psychiatric biomarker, or identifying drug-induced QT prolongation in clinical trials, wearable ECG technology is expanding what cardiac data can tell us and who it can help.
Question: What did the Ochsner Health study reveal about the heart–brain connection in epilepsy?
Short answer: The study showed that seizures can disrupt coordination between the heart’s upper and lower chambers, potentially reducing oxygen flow to the brain and other organs. Because epilepsy patients already face irregular heart rhythms and elevated cardiopulmonary risk—including the risk of SUDEP—continuous wearable ECG monitoring helped researchers capture uninterrupted data during and after seizures. This allowed them to identify dangerous cardiac patterns, flag high-risk patients for targeted interventions, and observe pre-seizure changes that could one day enable early warning alerts.
Question: Why is ECG monitoring standard in psychiatric clinical trials, and what added value does HRV provide?
Short answer: ECG monitoring is required in many psychiatric trials because certain medications (for conditions like schizophrenia, bipolar disorder, and depression) can prolong the QT interval, increasing the risk of dangerous cardiac events. Beyond this safety mandate, heart rate variability (HRV) offers research value as a biomarker of emotional regulation and systemic stress. Low HRV has been associated with neurological dysfunction and is being explored in studies of depression, anxiety, and PTSD, positioning cardiac markers as potential emotional biomarkers in mental health research.
Question: How is cardiac monitoring being applied outside cardiology, and what are some examples?
Short answer: Continuous cardiac data are informing multiple therapeutic areas. In oncology, cardiac biomarkers combined with behavioral data are being used to refine dosing strategies and detect treatment responses earlier. Sleep research links elevated nighttime heart rate and HRV patterns to increased risk of Type 2 diabetes. Studies of cognition have correlated heart rate with cognitive load in high-stress driving scenarios. These applications leverage continuous, high-fidelity monitoring to reveal clinically meaningful patterns that brief, clinic-based snapshots would miss.
Question: What advantages do wearable ECG monitors offer over traditional, clinic-based ECGs?
Short answer: Wearable ECGs provide continuous, real-world, high-fidelity data without restricting movement, making them well-suited to capturing quick or intermittent events. Traditional hospital monitors can detach during episodes like seizures, breaking the data stream at critical moments. In contrast, wearables maintain uninterrupted monitoring before, during, and after events, enabling richer insights and more reliable detection of clinically significant changes.
Question: What does the future look like for cardiac monitoring across therapeutic areas?
Short answer: Continuous wearable ECG technology is expanding what cardiac data can reveal and whom it can help. Beyond cardiology, it supports detection of seizure-related arrhythmias in neurology, tracking HRV as a psychiatric biomarker, and identifying drug-induced QT prolongation in clinical trials. As continuous, real-world data become standard, cardiac monitoring is poised to enable more proactive, data-driven care—potentially including early warnings and targeted interventions across diverse conditions.
Copyright © 2026 VivaLNK, Inc. All Rights Reserved.
No Comments Yet
Let us know what you think